Last reviewed · How we verify
Placebo plus clinical management
Placebo plus clinical management provides psychological benefit through expectation effects combined with structured clinical support and therapeutic interaction.
Placebo plus clinical management provides psychological benefit through expectation effects combined with structured clinical support and therapeutic interaction. Used for Substance use disorders (used as control/comparator in clinical trials).
At a glance
| Generic name | Placebo plus clinical management |
|---|---|
| Also known as | Placebo and Clinical Management |
| Sponsor | Centre for Addiction and Mental Health |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Addiction Medicine |
| Phase | FDA-approved |
Mechanism of action
This is a control arm or comparator treatment rather than a pharmacologically active drug. It leverages placebo response—the therapeutic benefit derived from patient expectation and the ritual of treatment—combined with clinical management including counseling, monitoring, and supportive care. The mechanism relies on psychobiological pathways activated by the therapeutic context rather than specific molecular targets.
Approved indications
- Substance use disorders (used as control/comparator in clinical trials)
Common side effects
Key clinical trials
- Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors (PHASE3)
- Testing Obeticholic Acid for Familial Adenomatous Polyposis (PHASE2)
- Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) (PHASE1)
- Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (PHASE3)
- Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma (PHASE2)
- Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) (PHASE2)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: